Journal
VACCINE
Volume 25, Issue 17, Pages 3277-3283Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2007.01.005
Keywords
modified vaccinia virus Ankara; HIV-1; clinical study
Categories
Funding
- MRC [G0502048, MC_U137884177, MC_U137884179] Funding Source: UKRI
- Medical Research Council [G0502048, MC_U137884179, MC_U137884177] Funding Source: researchfish
- Medical Research Council [MC_U137884177, MC_U137884179, G0502048] Funding Source: Medline
Ask authors/readers for more resources
The safety of attenuated poxviruses in HIV-1-infected individuals is an important consideration in their application as vaccine vectors, first, because new HIV-1 infections may occur in vaccine trials involving persons at high risk of infection and secondly, therapeutic vaccinations are a potential means to enhance virus-specific immune responses once infection has occurred. We administered a candidate modified vaccinia virus Ankara-vectored HIV-1 vaccine, MVA.HIVA, by intradermal injection to 16 chronically infected adults during highly active antiretroviral therapy. Vaccinations were well tolerated and there were no serious adverse events. No breakthrough viraemia occurred after immunisations or throughout follow-up. These data confirm the safety of MVA.HIVA in HIV-1-infected individuals and provide Support for further evaluation of MVA-vectored vaccines in prophylactic and therapeutic immunisation strategies. (c) 2007 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available